+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Allergy Vaccine Market by Route Of Administration, Allergens Targeted, Vaccine Type, Distribution Channel, Technology, Patient Age Group, End User - Global Forecast to 2030- Product Image
Allergy Vaccine Market by Route Of Administration, Allergens Targeted, Vaccine Type, Distribution Channel, Technology, Patient Age Group, End User - Global Forecast to 2030- Product Image
Sale

Allergy Vaccine Market by Route Of Administration, Allergens Targeted, Vaccine Type, Distribution Channel, Technology, Patient Age Group, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4905049
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Allergy Vaccine Market grew from USD 1.43 billion in 2024 to USD 1.60 billion in 2025. It is expected to continue growing at a CAGR of 11.55%, reaching USD 2.75 billion by 2030.

Navigating the Allergy Vaccine Revolution

Allergic diseases impact hundreds of millions worldwide, with rising environmental exposures and changing lifestyles intensifying sensitivities. Against this backdrop, immunotherapy has emerged as a cornerstone of long-term management, shifting focus from symptomatic relief to addressing underlying immune dysregulation. In this executive summary, we synthesize key developments, challenges, and strategic imperatives that define the allergy vaccine landscape today.

Through this concise overview, decision-makers will gain clarity on transformative scientific advances, the influence of emerging trade policies, critical market segments, and regional growth vectors. By bridging technical depth with practical guidance, the report equips stakeholders-from R&D leaders and commercial strategists to healthcare providers and investors-with the insights needed to capitalize on innovation and navigate regulatory complexities. This introduction sets the stage for a detailed exploration of the forces reshaping allergy vaccine development and commercialization.

Seismic Shifts Redefining Allergy Treatment Paradigms

Scientific innovation and evolving patient expectations are converging to redefine allergy immunotherapy. Precision medicine techniques now enable allergen component-resolved diagnostics, informing tailored vaccine formulations that enhance efficacy and safety profiles. Moreover, advances in recombinant DNA technology have accelerated the development of standardized allergens, reducing batch variability and improving regulatory predictability.

Digital health solutions are further transforming care delivery, with mobile applications and remote monitoring tools empowering patients to adhere to complex dosing regimens and report outcomes in real time. In parallel, novel adjuvant systems are being optimized to amplify immune tolerance while minimizing side effects, a shift that elevates the therapeutic index of both subcutaneous and sublingual approaches. These collective shifts underscore a broader industry movement toward patient-centric, data-driven immunotherapy that promises to reshape market dynamics and delivery models going forward.

Impacts of US Tariff Policies on Vaccine Supply Chains

In 2025, the introduction of new U.S. tariffs on imported allergen extracts and raw materials has reverberated across global supply chains. Manufacturers reliant on European and Asian antigen sources are facing elevated input costs that, in aggregate, have compressed margins and necessitated price adjustments in downstream markets. The cumulative tariff impact has also accelerated the repatriation of certain production processes, prompting investments in domestic fermentation and purification facilities to mitigate future trade volatility.

Healthcare providers and payers are responding by scrutinizing cost-effectiveness, driving demand for accelerated dosing regimens that reduce clinic visits and overall treatment expenditure. Concurrently, some companies are exploring strategic partnerships with domestic extract producers to safeguard supply continuity. As tariffs continue to influence sourcing decisions and contract negotiations, stakeholders must balance near-term cost pressures with long-term capacity expansion to maintain both competitiveness and patient access.

Unpacking Complex Segmentation to Drive Market Precision

A granular examination of market subsegments highlights where growth and innovation intersect. Within subcutaneous administration, accelerated dosing protocols are gaining momentum as they condense treatment timelines, while standard dosing retains its stronghold among established clinical practices. On the sublingual front, liquid drops remain predominant due to patient familiarity, yet tablet formulations are advancing rapidly, propelled by ease of use and improved stability.

When considering allergens targeted, perennial sensitivities driven by animal dander and dust mite allergens continue to dominate therapy volumes, but emerging research on mold and pollen components is driving seasonal demand spikes during peak allergen seasons. Monovalent vaccines focus on single allergen specificity and are favored in precision-diagnosed cases, whereas polyvalent formulations address multiple triggers and are central to broader patient cohorts.

Distribution patterns reveal that hospital pharmacies are pivotal for initiating immunotherapy under specialist supervision, while the convenience of online pharmacies is unlocking home-based treatment models. Retail pharmacies remain essential for ongoing maintenance dosing. On the technology axis, recombinant platforms are outpacing traditional extracts by delivering high-purity products, even as established extract methodologies persist due to lower up-front development costs.

Age-based considerations show adult segments forming the backbone of current demand, yet pediatric cohorts are poised for expansion as early-intervention strategies gain traction. Geriatric populations, with unique comorbidities and immunosenescence challenges, are also receiving dedicated formulation attention. Finally, end-user venues such as clinics deliver primary immunotherapy services, whereas hospitals provide specialized care and home healthcare providers are scaling programs that enable remote dosing under professional guidance.

Regional Dynamics Shaping Future Growth Opportunities

Market trajectories vary significantly by geography. In the Americas, robust reimbursement frameworks and high adoption of novel immunotherapies have cemented this region’s leadership position. North America in particular showcases strong clinical trial activity and a competitive manufacturer ecosystem, while Latin America markets are advancing through public-private partnerships and regional production initiatives.

Across Europe, Middle East & Africa, regulatory harmonization under frameworks such as the European Medicines Agency bolsters cross-border commercialization, yet heterogeneous reimbursement landscapes in the Middle East and North Africa necessitate bespoke market access strategies. Government-led immunization programs in the Gulf Cooperation Council countries are expanding allergy vaccine uptake, and emerging markets in Eastern Europe are attracting investment due to favorable manufacturing incentives.

Asia-Pacific stands out for its rapid growth rates, driven by escalating allergy prevalence in densely populated nations like China and India. Expanding healthcare infrastructure, rising per-capita spending, and an influx of international players are catalyzing the establishment of regional production hubs. In Southeast Asia and Australia, e-commerce channels are gaining traction, challenging traditional pharmacy models and improving accessibility in remote areas.

Strategic Moves by Leading Industry Players

Leading immunotherapy enterprises are pursuing differentiated strategies to solidify market positions. ALK-Abelló has accelerated its shift toward recombinant allergen platforms, leveraging partnerships to broaden its global footprint. DBV Technologies continues to champion its epicutaneous delivery system, advancing late-stage clinical trials that, if successful, could disrupt sublingual and subcutaneous norms.

Stallergenes Greer is strengthening its presence in North American markets through targeted acquisitions and enhanced manufacturing capacity, while LETI Pharma focuses on novel adjuvant research in Europe, aiming to optimize immune tolerance induction. Allergy Therapeutics has diversified its portfolio via licensing agreements in Asia-Pacific, coupling traditional extract expertise with local distribution networks. Emerging biotechnology firms are also forging collaborative alliances with major pharmaceutical partners to co-develop next-generation vaccines that promise improved safety and operational efficiency.

Strategic Imperatives for Allergy Vaccine Market Leaders

Industry leaders must adopt a multifaceted approach to capture evolving market opportunities. Prioritizing investment in recombinant technologies can yield standardized, high-purity products that meet stringent regulatory requirements and command premium pricing. Concurrently, optimizing dosing regimens-whether through accelerated subcutaneous protocols or user-friendly sublingual tablets-will enhance patient convenience and adherence, reducing overall treatment costs.

Expanding distribution partnerships with online pharmacy platforms and home healthcare services will unlock new patient segments and alleviate clinic capacity constraints. Engaging payers early to demonstrate cost-effectiveness and long-term value is critical for securing favorable reimbursement terms. Segment-specific strategies should address the unique needs of pediatric and geriatric populations, ensuring tailored safety profiles and dosing schedules.

To mitigate supply-chain and tariff risks, building resilient, geographically diversified production capabilities is essential. Lastly, integrating digital health tools for real-time monitoring and outcome tracking will not only enhance patient engagement but also generate valuable real-world evidence to support product differentiation and market access.

Robust Methodology Underpinning Comprehensive Insights

This report’s insights are founded on a rigorous research framework combining primary and secondary methodologies. Primary research included in-depth interviews with key opinion leaders such as allergists, immunologists, and health system executives across major markets. These qualitative insights were supplemented by quantitative data extracted from regulatory filings, company financial reports, clinical trial registries, and industry publications.

Secondary research encompassed analysis of trade association reports, government policies on tariff schedules, and international reimbursement guidelines. A detailed segmentation model was constructed based on administration routes, allergens targeted, vaccine types, distribution channels, technology platforms, patient age groups, and end-user settings. Regional analysis incorporated macroeconomic indicators, healthcare expenditure data, and demographic trends.

All findings underwent triangulation through cross-validation with industry experts to ensure accuracy and relevance. The methodology emphasizes transparency, reproducibility, and ongoing updates to reflect regulatory changes and emerging market developments.

Concluding Perspectives on the Allergy Vaccine Market

The allergy vaccine sector stands at a pivotal juncture where scientific breakthroughs, policy shifts, and evolving patient expectations converge. Manufacturers that harness recombinant technologies and optimize administration formats will set new standards for safety and efficacy. Simultaneously, strategic navigation of tariff landscapes and supply-chain diversification will be paramount to maintaining competitive cost structures.

Segment-driven approaches-grounded in precise understanding of administration modalities, allergen profiles, demographic needs, and distribution preferences-will guide successful product launches and lifecycle management. Regional nuances demand customized market access strategies backed by strong local partnerships and digital engagement channels. Industry incumbents and new entrants alike must prioritize collaboration, innovation, and data-driven decision making to thrive in this dynamic environment.

By integrating these critical insights and recommendations, stakeholders can position themselves to deliver superior patient outcomes, secure sustainable growth, and drive the next wave of immunotherapy evolution.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Subcutaneous Immunotherapy
      • Accelerated Doses
      • Standard Doses
    • Sublingual Immunotherapy
      • Drops
      • Tablets
  • Allergens Targeted
    • Perennial Allergens
      • Animal Dander
      • Dust Mite
    • Seasonal Allergens
      • Molds
      • Pollen
  • Vaccine Type
    • Monovalent
    • Polyvalent
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Technology
    • Recombinant
    • Traditional Extract
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
  • End User
    • Clinics
    • Home Healthcare
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • ALK-Abelló A/S
  • Stallergenes Greer LLC
  • Allergopharma GmbH & Co. KG
  • Merck & Co., Inc.
  • DBV Technologies S.A.
  • Allergy Therapeutics plc
  • Laboratorios LETI, S.L.
  • HAL Allergy B.V.
  • Bencard Allergie GmbH
  • Torii Pharmaceutical Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Allergy Vaccine Market, by Route Of Administration
8.1. Introduction
8.2. Subcutaneous Immunotherapy
8.2.1. Accelerated Doses
8.2.2. Standard Doses
8.3. Sublingual Immunotherapy
8.3.1. Drops
8.3.2. Tablets
9. Allergy Vaccine Market, by Allergens Targeted
9.1. Introduction
9.2. Perennial Allergens
9.2.1. Animal Dander
9.2.2. Dust Mite
9.3. Seasonal Allergens
9.3.1. Molds
9.3.2. Pollen
10. Allergy Vaccine Market, by Vaccine Type
10.1. Introduction
10.2. Monovalent
10.3. Polyvalent
11. Allergy Vaccine Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Allergy Vaccine Market, by Technology
12.1. Introduction
12.2. Recombinant
12.3. Traditional Extract
13. Allergy Vaccine Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Allergy Vaccine Market, by End User
14.1. Introduction
14.2. Clinics
14.3. Home Healthcare
14.4. Hospitals
15. Americas Allergy Vaccine Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Allergy Vaccine Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Allergy Vaccine Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. ALK-Abelló A/S
18.3.2. Stallergenes Greer LLC
18.3.3. Allergopharma GmbH & Co. KG
18.3.4. Merck & Co., Inc.
18.3.5. DBV Technologies S.A.
18.3.6. Allergy Therapeutics plc
18.3.7. Laboratorios LETI, S.L.
18.3.8. HAL Allergy B.V.
18.3.9. Bencard Allergie GmbH
18.3.10. Torii Pharmaceutical Co., Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. ALLERGY VACCINE MARKET MULTI-CURRENCY
FIGURE 2. ALLERGY VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. ALLERGY VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ALLERGY VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ALLERGY VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ALLERGY VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. ALLERGY VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ALLERGY VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ALLERGY VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ACCELERATED DOSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ALLERGY VACCINE MARKET SIZE, BY STANDARD DOSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ANIMAL DANDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DUST MITE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ALLERGY VACCINE MARKET SIZE, BY MOLDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ALLERGY VACCINE MARKET SIZE, BY POLLEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ALLERGY VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ALLERGY VACCINE MARKET SIZE, BY POLYVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TRADITIONAL EXTRACT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ALLERGY VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 68. CANADA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 70. CANADA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 71. CANADA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 72. CANADA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 73. CANADA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. CANADA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. CANADA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. CANADA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. GERMANY ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 135. GERMANY ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 136. GERMANY ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 137. GERMANY ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 138. GERMANY ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 140. GERMANY ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. GERMANY ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. GERMANY ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 143. GERMANY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. FRANCE ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 154. FRANCE ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. ITALY ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. ITALY ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 168. ITALY ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 169. ITALY ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 170. ITALY ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 171. ITALY ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 172. ITALY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 173. ITALY ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. ITALY ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 175. ITALY ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. ITALY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SPAIN ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. SPAIN ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 179. SPAIN ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 180. SPAIN ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 181. SPAIN ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 182. SPAIN ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 183. SPAIN ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 184. SPAIN ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. SPAIN ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. SPAIN ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. SPAIN ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. DENMARK ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. DENMARK ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 223. DENMARK ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. DENMARK ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 225. DENMARK ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 227. DENMARK ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 228. DENMARK ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. DENMARK ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. DENMARK ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. QATAR ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. QATAR ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 245. QATAR ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 246. QATAR ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 247. QATAR ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 248. QATAR ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 249. QATAR ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 250. QATAR ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. QATAR ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 252. QATAR ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. QATAR ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. FINLAND ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. FINLAND ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. FINLAND ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 257. FINLAND ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 258. FINLAND ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 259. FINLAND ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 260. FINLAND ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 261. FINLAND ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. FINLAND ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. FINLAND ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 264. FINLAND ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. SWEDEN ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. NIGERIA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. EGYPT ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. EGYPT ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 289. EGYPT ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 290. EGYPT ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 291. EGYPT ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 294. EGYPT ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. EGYPT ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 296. EGYPT ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 297. EGYPT ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. TURKEY ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. TURKEY ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 300. TURKEY ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 301. TURKEY ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 302. TURKEY ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 303. TURKEY ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 304. TURKEY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 305. TURKEY ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. TURKEY ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. TURKEY ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 308. TURKEY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. NORWAY ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 321. NORWAY ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 322. NORWAY ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 323. NORWAY ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 324. NORWAY ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 325. NORWAY ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 326. NORWAY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 327. NORWAY ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. NORWAY ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 329. NORWAY ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 330. NORWAY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. POLAND ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 332. POLAND ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 333. POLAND ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 334. POLAND ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2030 (USD MILLION)
TABLE 335. POLAND ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 336. POLAND ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2030 (USD MILLION)
TABLE 337. POLAND ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 338. POLAND ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 339. POLAND ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 340. POLAND ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 341. POLAND ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION

Companies Mentioned

The companies profiled in this Allergy Vaccine market report include:
  • ALK-Abelló A/S
  • Stallergenes Greer LLC
  • Allergopharma GmbH & Co. KG
  • Merck & Co., Inc.
  • DBV Technologies S.A.
  • Allergy Therapeutics plc
  • Laboratorios LETI, S.L.
  • HAL Allergy B.V.
  • Bencard Allergie GmbH
  • Torii Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.75 Billion
Compound Annual Growth Rate11.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Allergy Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Allergy Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Allergy Immunotherapy Market Report 2025 - Product Image

Allergy Immunotherapy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Allergy Immunotherapy Market by Treatment Type, Allergen Type, Immunotherapy Delivery Form, Technology Platform, Allergy Type, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Allergy Immunotherapy Market by Treatment Type, Allergen Type, Immunotherapy Delivery Form, Technology Platform, Allergy Type, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
IgE Allergy Blood Tests Market by Test Type, Technology, Application, End User, Distribution Channel - Global Forecast to 2030 - Product Image

IgE Allergy Blood Tests Market by Test Type, Technology, Application, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Allergy Immunotherapy Market Size, Share & Trends Analysis Report By Treatment Type (Subcutaneous Immunotherapy) By Type, By Allergy Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Allergy Immunotherapy Market Size, Share & Trends Analysis Report By Treatment Type (Subcutaneous Immunotherapy) By Type, By Allergy Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From

About the Allergy Vaccine Market

The Allergy Vaccine market is a subset of the Vaccines market, which is composed of products designed to prevent or reduce the severity of infectious diseases. Allergy Vaccines are specifically designed to reduce the severity of allergic reactions, such as hay fever, asthma, and food allergies. These vaccines are typically administered through a series of injections, which can be tailored to the individual patient's needs. Allergy Vaccines are becoming increasingly popular as a way to reduce the burden of allergic reactions, and are being used in both adults and children. They are also being used in combination with other treatments, such as antihistamines and immunotherapy, to provide a more comprehensive approach to managing allergies. Some companies in the Allergy Vaccine market include ALK-Abello, Stallergenes Greer, Allergy Therapeutics, and DBV Technologies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.